1. Inicio
  2. Publicaciones
  3. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bento L.
  • Gutiérrez A.
  • Martínez C.
  • Consejo Ortí Verdet M.
  • Sorribes M.
  • Caballero A.C.
  • Peña M.
  • Pérez A.
  • Jiménez-Ubieto A.
  • Medina L.
  • Bastos-Oreiro M.
  • Caldas-González P.F.
  • Navarro B.
  • Salcedo I.
  • Abrisqueta P.
  • Español I.
  • Cornago J.
  • Martín-Moro F.
  • García L.
  • Gómez P.
  • Varela M.R.
  • Puente M.
  • Zanabili J.
  • Zudaire T.
  • Zeberio I.
  • del Campo R.
  • González L.
  • González P.
  • Blázquez C.
  • Rovira J.
  • Sitges M.
  • Franch-Sarto M.
  • Cabero A.
  • Mussetti A.
  • Sampol A.
  • Sureda A.
  • Caballero D.
  • García-Sancho A.M.

Grupos

Abstract

We performed a retrospective multicenter study including 791 patients with relapsed/ refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as =3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as =3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under.

Datos de la publicación

ISSN/ISSNe:
2473-9529, 2473-9537

Blood Advances  ELSEVIER

Tipo:
Article
Páginas:
3281-3292
PubMed:
40163764
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,795 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • anthracycline; carboplatin; cisplatin; cytarabine; dexamethasone; etoposide; gemcitabine; ifosfamide; melphalan; methylprednisolone; rituximab; thiotepa; adult; aged; Article; autologous stem cell transplantation; cancer chemotherapy; cancer radiotherapy; cancer recurrence; cancer survival; chemosensitive disease; chimeric antigen receptor T cell; clinical outcome; cohort analysis; diffuse large B cell lymphoma; disease control; disease free survival; drug efficacy; female; follicular lymphoma; follow up; GELTAMO study; human; immunotherapy; male; mortality; multicenter study (topic); multivariate analysis; outcome assessment; overall response rate; overall survival; progression free survival; protein expression; recurrence free survival; relapse; retrospective study; stem cell transplantation; survival analysis

Cita

Compartir